A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

NCT05593094 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

210

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors
HER2-positive Breast Cancer

Interventions

DRUG: ZN-A-1041
DRUG: ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1b
DRUG: ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1b
DRUG: ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1b
DRUG: ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1c
DRUG: ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1c
DRUG: ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1c

Sponsor

Hoffmann-La Roche